ENDRA jumps 12% on surprise profit, advances Noble Africa merger with $50M raise
What's the deal? ENDRA Life SciencesDealroom has a profile for this one. Try Dealroom → reported second-quarter 2026 net income of roughly $160,000, swinging from a $1.2 million loss a year earlier, and updated investors on its planned merger with Noble AfricaDealroom has a profile for this one. Try Dealroom →. Shares rose 12.06% to $6.37 on the news.
The numbers: Total operating expenses climbed to about $1.5 million from $1.3 million, driven partly by $542,000 in non-cash stock-based compensation, up from $89,000. Research and development expenses fell 39% year over year, and sales and marketing dropped 92%. The profit swing came largely from about $1.6 million in other income tied to gains on the company's digital asset treasury.
Why now? On June 25, 2026, ENDRA — a medical technology company developing thermoacoustic imaging for steatotic liver disease — signed a definitive merger agreement with ASP IsotopesDealroom has a profile for this one. Try Dealroom →, Noble Africa, and RenergenDealroom has a profile for this one. Try Dealroom →. Noble Africa will merge into an ENDRA subsidiary, and the combined company is expected to be renamed Noble Africa Inc.
What's the endgame? The deal is intended to give ENDRA stockholders exposure to Renergen's Virginia Gas Project in South Africa. Noble Africa has signed subscription agreements for a private placement expected to raise roughly $50 million in gross proceeds.
The money position: As of June 30, ENDRA held about $1.7 million in cash, $3.8 million in restricted cash, and $1.9 million in its digital asset treasury. It also completed a $3.8 million private placement on May 28, with those proceeds classified as restricted cash.
What could go wrong? The merger is expected to close in the fourth quarter of 2026, but remains subject to customary closing conditions, including stockholder and regulatory approvals. ENDRA said it is working with its partners to satisfy those conditions.
The signal: The transaction would pivot a struggling liver-imaging company into a South African gas play, with a reverse-merger structure offering a public-market path for Noble Africa. For now, ENDRA's quarterly profit rests largely on digital asset gains rather than its core technology.
Read more: rttnews.com
Image credit: Generated with Gemini
